Capecitabine 500mg Tablets

Capecitabine 500mg Tablets is a sophisticated oral fluoropyrimidine carbamate that functions as a “prodrug,” meaning it is pharmacologically inactive when first swallowed. It is designed to be converted into its active form, 5-fluorouracil (5-FU), through a specific three-step enzymatic process within the body. The final step of this conversion is catalyzed by thymidine phosphorylase, an enzyme that is often found at much higher concentrations in tumor tissue than in healthy tissue. This tumor-selective activation allows Capecitabine to deliver high concentrations of the cytotoxic agent directly to the cancer site while minimizing systemic toxicity. Once activated, the 5-FU mimics natural building blocks of DNA and RNA, inhibiting the enzyme thymidylate synthase. This inhibition blocks the synthesis of thymidine, an essential component of DNA, thereby halting cell division and triggering tumor cell death. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for ambulatory cancer care, offering the efficacy of continuous intravenous infusion without the need for a pump or port.

The 500mg tablet is the standard adult dosing unit used to construct the daily regimen, which is strictly calculated based on Body Surface Area (BSA). Standard protocols typically require 1000 mg/m² or 1250 mg/m² twice daily. The 500mg strength (often peach-colored and film-coated) allows for manageable pill counts when reaching these high total daily doses (e.g., 3 to 4 tablets per dose). The medication is taken orally twice a day, typically for 14 consecutive days followed by a 7-day rest period, creating a cyclical “2 weeks on, 1 week off” schedule.

Indications / Uses of Capecitabine 500mg Tablets

Capecitabine 500mg Tablets is commonly prescribed for the specialized management of the following malignancies:

• Colorectal Cancer: It is indicated as a single agent for adjuvant treatment in patients with Stage III (Dukes’ C) colon cancer after surgery. It is also a first-line treatment for metastatic colorectal cancer, often used alone or in combination with oxaliplatin (CAPOX regimen).
• Breast Cancer: The medication is used in combination with docetaxel for the treatment of metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. It is also indicated as a monotherapy for patients resistant to both paclitaxel and anthracyclines.
• Gastric/Esophageal Cancer: It is frequently used in combination with platinum-based chemotherapy (e.g., oxaliplatin or cisplatin) for the treatment of advanced or metastatic gastric and gastroesophageal junction adenocarcinomas.

Key Features

• Oral Prodrug Technology: The primary feature of Capecitabine 500mg Tablets is its ability to generate 5-FU preferentially in tumor tissue, enhancing efficacy and reducing certain systemic side effects.
• Mimics Continuous Infusion: It maintains sustained cytotoxic levels in the blood similar to a continuous IV infusion of 5-FU, but with the convenience of a pill.
• Home-Based Therapy: It eliminates the need for central venous catheters (ports) and portable infusion pumps, significantly improving patient quality of life.
• 500mg High-Potency Unit: The 500mg tablet size reduces the “pill burden” for patients compared to using only 150mg tablets.
• Flexible Dosing: The tablet strength supports easy dose modifications (reductions) to manage toxicity.

Storage for Capecitabine 500mg Tablets

To preserve the pharmacological stability and ultimate potency of the active ingredients, Capecitabine 500mg Tablets should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F to 86°F). It is vital to keep the tablets in their original container with the lid tightly closed to protect them from moisture. For maximum safety, always store Capecitabine 500mg Tablets in a secure, high location that is strictly out of the reach and sight of children and pets.

Important Note on Capecitabine 500mg Tablets

The administration of Capecitabine 500mg Tablets is associated with a specific risk of Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia). This manifests as redness, swelling, pain, and peeling on the palms of the hands and soles of the feet. If severe, it can be debilitating. Patients must be taught to recognize early signs and may need dose interruptions or reductions.

Warfarin Interaction (Black Box Warning): Capecitabine significantly increases the effect of the blood thinner warfarin, leading to a high risk of bleeding. This interaction can occur even months after stopping Capecitabine. INR levels must be monitored very frequently.

DPD Deficiency: Patients with a genetic lack of the enzyme Dihydropyrimidine Dehydrogenase (DPD) cannot metabolize 5-FU and are at risk of life-threatening toxicity (severe diarrhea, neutropenia, neurotoxicity) even after a single dose. Testing for DPD deficiency is increasingly recommended. Diarrhea is a common side effect; patients should have anti-diarrheal medication (loperamide) on hand. By strictly following these professional guidelines and monitoring INR/skin changes, healthcare providers can safely maximize the therapeutic benefits of Capecitabine 500mg Tablets.